Reviewing Nutra Pharma (NPHC) and Mediwound (MDWD)

Nutra Pharma (OTCMKTS:NPHC) and Mediwound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Institutional and Insider Ownership

0.0% of Nutra Pharma shares are owned by institutional investors. Comparatively, 32.6% of Mediwound shares are owned by institutional investors. 61.5% of Nutra Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nutra Pharma and Mediwound, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nutra Pharma 0 0 0 0 N/A
Mediwound 0 0 3 0 3.00

Mediwound has a consensus target price of $11.33, indicating a potential upside of 95.40%. Given Mediwound’s higher probable upside, analysts clearly believe Mediwound is more favorable than Nutra Pharma.

Valuation and Earnings

This table compares Nutra Pharma and Mediwound’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nutra Pharma $120,000.00 10.00 -$4.02 million N/A N/A
Mediwound $2.50 million 62.76 -$22.14 million ($0.62) -9.35

Nutra Pharma has higher earnings, but lower revenue than Mediwound.


This table compares Nutra Pharma and Mediwound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nutra Pharma -4,940.00% N/A -1,875.70%
Mediwound -783.30% -210.90% -33.92%

Volatility & Risk

Nutra Pharma has a beta of 6.12, suggesting that its stock price is 512% more volatile than the S&P 500. Comparatively, Mediwound has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.


Mediwound beats Nutra Pharma on 7 of the 11 factors compared between the two stocks.

Nutra Pharma Company Profile

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Nyloxin, a topical therapy for chronic pain in horses. It is also developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes; RPI-78 for pain and arthritis; and RPI-70 for pain. The company has a collaboration agreement with the International Security Group to develop nerve agent counter measures. Nutra Pharma Corp. was founded in 2000 and is based in Coral Springs, Florida.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive News & Ratings for Nutra Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutra Pharma and related companies with's FREE daily email newsletter.

Leave a Reply